ArticlePloS one2020
A Systematic comparison of in vitro cell uptake and in vivo biodistribution for three classes of gold nanoparticles with saturated PEG coatings.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Biogenic Metal Nanoparticles from Indian Flora as Programmable Bio-Interfaces: From Phytochemical Coronas to Precision Nanomedicine.International journal of molecular sciences · 2026Review
- Interaction of PEGylated gold nanorods with HIF-1α/Ki-67 in inhibiting immunosuppression and arresting cancer proliferation in murine fibrosarcoma.Scientific reports · 2026Article
- Targeted Nanoboron Delivery Platform for Boron Neutron Capture Therapy in Refractory Solid Tumors.International journal of nanomedicine · 2026Review
- Arabinogalactan-Functionalized Gold Nanoparticles Demonstrated Remarkable Anticancer Therapeutic Effect against Hepatocellular Carcinoma.Molecular pharmaceutics · 2025Article
- Optimization of Metal-Based Nanoparticle Composite Formulations and Their Application in Wound Dressings.International journal of nanomedicine · 2025Review
- Impacts of polyethylene glycol (PEG) dispersity on protein adsorption, pharmacokinetics, and biodistribution of PEGylated gold nanoparticles.RSC advances · 2024Article
- Tackling breast cancer with gold nanoparticles: twinning synthesis and particle engineering with efficacy.Nanoscale advances · 2024Review
- Mitochondrial DNA as a target for analyzing the biodistribution of cell therapy products.Scientific reports · 2024Article
- Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Extracellular vesicles: emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy.Drug delivery · 2022Review
- Biological Response of Human Cancer Cells to Ionizing Radiation in Combination with Gold Nanoparticles.Cancers · 2022Article
- Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances.Drug delivery and translational research · 2022Article
- Analysis of Nanomaterials on Biological and Environmental Systems and New Analytical Methods for Improved Detection.International journal of molecular sciences · 2022Article
- Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases.Vaccines · 2022Review
- Revisiting the outstanding questions in cancer nanomedicine with a future outlook.Nanoscale advances · 2022Review
- The Role ofFrontiers in digital health · 2022Review
- Impact of administration route on nanocarrier biodistribution in a murine colitis model.Journal of experimental nanoscience · 2022Article
- Understanding the influence of experimental factors on bio-interactions of nanoparticles: Towards improving correlation between in vitro and in vivo studies.Archives of biochemistry and biophysics · 2020Review
- Distinct Proteins in Protein Corona of Nanoparticles Represent a Promising Venue for Endogenous Targeting - Part II: In vitro and in vivo Kinetics Study.International journal of nanomedicine · 2020Article
- Dual-Modality Therapy: Synergistic Enhancement of Radio-Hyperthermia by Gold-Gold Sulfide Nanoparticles in MCF-7 Cells.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A great deal of attention has been focused on nanoparticles for cancer therapy, with the promise of tumor-selective delivery. However, despite intense work in the field over many years, the biggest obstacle to this vision remains extremely low delivery efficiency of nanoparticles into tumors. Due to the cost, time, and impact on the animals for in vivo studies, the nanoparticle field predominantly uses cellular uptake assays as a proxy to predict in vivo outcomes. Extensive research has focused on decreasing macrophage uptake in vitro as a proxy to delay nanoparticle accumulation in the mononuclear phagocytic system (MPS), mainly the liver and spleen, and thereby increase tumor accumulation. We have recently reported novel synthetic methods employing small molecule crosslinkers for the controlled assembly of small nanoparticles into larger aggregates and found that these nanoaggregates had remarkably high surface coverage and low cell uptake, even in macrophages. We further found that this extremely low cellular uptake could be recapitulated on solid gold nanoparticles by densely coating their surface with small molecules. Here we report our studies on the biodistribution and clearance of these materials in comparison to more conventional PEGylated gold nanoparticles. It was expected that the remarkably low macrophage uptake in vitro would translate to extended blood circulation time in vivo, but instead we found no correlation between either surface coverage or in vitro macrophage cell uptake and in vivo blood circulation. Gold nanoaggregates accumulate more rapidly and to a higher level in the liver compared to control gold nanoparticles. The lack of correlation between in vitro macrophage uptake and in vivo blood circulation suggests that the field must find other in vitro assays to use as a primary proxy for in vivo outcomes or use direct in vivo experimentation as a primary assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.